E Fund Hang Seng SCHK Innovative Drug ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

CMBC International and DBS Maintain Buy Rating for BeiGene

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

159892

ARKG

512290

159316

516500

516930

588130

159992

159849

159837

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

prnewswire

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

iShares Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

iShares US Pharma

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Bosera Hang Seng Health Care ETF(QDII)

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

01801

159570

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.

PUBT

iShares Global Healthcare

Penghua CSI HK Connect Health Care Composite ETF

BlackRock, Inc.

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer

ZLAB

09688

520500

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

Ping An CSI Medicine and Medical Device Innovation ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

Ring Therapeutics®, a biotech firm based in Cambridge, Massachusetts, disclosed fresh insights on its Vector Conjugate system and VectorBricks™ in vitro manufacturing technology. The company unveiled this data on May 14, 2026. The innovative platform aims to develop precise medications.

Unusual Whales

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

01177

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

SBP GROUP

GlaxoSmithKline plc

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Goldman Sachs

GS Hldg R

GSK plc Sponsored ADR

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

02268

WXXWY

02269

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

TransThera reports promising tinengotinib results in advanced solid tumors

E Fund Hang Seng SCHK Innovative Drug ETF(159316.SZ)